Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 5, Pages 605-617
Publisher
Informa Healthcare
Online
2012-03-14
DOI
10.1517/13543784.2012.670219
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB).
- (2017) P. Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin combined with the vascular-disrupting agent CYT997 for recurrent glioblastoma multiforme.
- (2017) J. Lickliter et al. JOURNAL OF CLINICAL ONCOLOGY
- Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC).
- (2017) R. Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
- (2017) Sith Sathornsumetee et al. NEURO-ONCOLOGY
- AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- (2011) O. L. Chinot et al. ADVANCES IN THERAPY
- Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processing
- (2011) Takayuki Ikeda et al. BIOCHEMICAL JOURNAL
- Antiangiogenesis Enhances Intratumoral Drug Retention
- (2011) J. Ma et al. CANCER RESEARCH
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
- (2011) R. G. Bagley et al. CLINICAL CANCER RESEARCH
- The role of β3-integrins in tumor angiogenesis: context is everything
- (2011) Stephen D Robinson et al. CURRENT OPINION IN CELL BIOLOGY
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients
- (2011) Andrew D. Norden et al. JOURNAL OF NEURO-ONCOLOGY
- Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
- (2011) S. R. Brave et al. MOLECULAR CANCER THERAPEUTICS
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
- (2011) Teri N. Kreisl et al. NEURO-ONCOLOGY
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
- (2011) N. Butowski et al. NEURO-ONCOLOGY
- Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
- (2011) W. B. Pope et al. NEUROLOGY
- Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy
- (2011) J. Yao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transdifferentiation of glioblastoma cells into vascular endothelial cells
- (2011) Y. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bevacizumab does not increase the risk of remote relapse in malignant glioma
- (2010) Antje Wick et al. ANNALS OF NEUROLOGY
- A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
- (2010) S. El Hallani et al. BRAIN
- PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
- (2010) Carlos Bais et al. CELL
- Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease
- (2010) Sara Van de Veire et al. CELL
- Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay
- (2010) Petra Knizetova et al. CELL CYCLE
- The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype
- (2010) John M. Heddleston et al. CELL CYCLE
- Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation
- (2010) Mackenzie C. McGee et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Change in Pattern of Relapse After Antiangiogenic Therapy in High-Grade Glioma
- (2010) Ashwatha Narayana et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
- (2010) Sridharan Gururangan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
- (2010) Roger Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
- (2010) Albert Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma
- (2010) B. Neyns et al. JOURNAL OF NEURO-ONCOLOGY
- Tie1-Tie2 Interactions Mediate Functional Differences between Angiopoietin Ligands
- (2010) Tom C.M. Seegar et al. MOLECULAR CELL
- Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
- (2010) Lucia Ricci-Vitiani et al. NATURE
- Glioblastoma stem-like cells give rise to tumour endothelium
- (2010) Rong Wang et al. NATURE
- The paradoxical effect of bevacizumab in the therapy of malignant gliomas
- (2010) E. M. Thompson et al. NEUROLOGY
- Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
- (2009) Joost JC Verhoeff et al. BMC CANCER
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
- (2009) Philip H. Gutin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
- (2009) Gabriele D. Maurer et al. NEURO-ONCOLOGY
- Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
- (2009) P. L. Nghiemphu et al. NEUROLOGY
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
- (2008) C Le Tourneau et al. BRITISH JOURNAL OF CANCER
- Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
- (2008) Tom Mikkelsen et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012
- (2008) Tobey J. MacDonald et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
- (2008) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF Trap induces antiglioma effect at different stages of disease
- (2008) Candelaria Gomez-Manzano et al. NEURO-ONCOLOGY
- Safety of anticoagulation use and bevacizumab in patients with glioma
- (2008) Phioanh (Leia) Nghiemphu et al. NEURO-ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now